Using a targeted lung cancer panel, we found one KRAS and two TP53 mutations, with sorted sample allele frequencies increased from <3% up to ~20% and 1–6% up to ~80%, respectively (Fig. 3c). Here, KRAS is linked to lung carcinoma.